Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Phosphodiesterase 1 (PDE1) Regulation of Myocardial Calcium and Function

Award Number: R01HL171586
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/22/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2028

Group Awards By:

View Award Description

Phosphodiesterase 1 (PDE1) Regulation of Myocardial Calcium and Function - Project Summary The body has innate mechanisms to increase cardiac function under varying physiologic conditions. Inotropes, a class of heart failure drugs, utilize these mechanisms to therapeutically improve cardiac function. Some inotropes, however, are safe while others increase the risk of side effects like arrhythmias. This is an intriguing question when considering two drugs that improve heart function by inhibiting phosphodiesterases (PDEs). PDE inhibition mechanistically increases cyclic nucleotide cAMP levels and thus activate protein kinase A (PKA) cell signaling pathways in the heart. Pharmacologic inhibition of PDEs 1 or 3 augments cardiac function. Chronic PDE3 inhibition (PDE3i), however, increases fatal arrhythmias in patients. While the arrhythmogenic effects of chronic PDE1i remains unknown, acute inhibition is safe. We do not yet fully understand how PDE 1 or 3 inhibition mechanisms differ to explain these differences. The goal of this study is to uncover fundamental cardiac contractility mechanisms that distinguish the actions of the two inotropes. We test the central hypothesis that appropriate compartmentalized control of cAMP/PKA signaling will accomplish specified improvement in cardiac contractility. This is supported by our prior findings that PDE3i activated PKA signaling to increase L-type calcium channel (LTCC) and the sarcoplasmic reticulum (SR) calcium load, but that PDE1i selectively augmented LTCC activity. And while β-blockers abrogated the inotropic effects of PDE3i, the effects for PDE1i persisted. In preliminary data, we show that sarcolemmal cAMP is predominantly hydrolyzed by PDE1 in living myocytes. Furthermore, PDE4, but not PDE1, inhibition synergistically increase cAMP that is produced upon β-adrenergic receptor stimulation. The investigation of compartmentalized myocardial contractility mechanisms in health and disease will be divided into three aims. In Aim 1, we will delineate cyclic nucleotides-activated pathways downstream of PDE1 inhibition that increase LTCC function. This will be done using biosensors of cAMP, cGMP, and PKA in isolated myocytes using Forster resonance energy transfer (FRET) imaging. LTCC function will be tested using patch clamping. Healthy, heart failure guinea pigs, and genetically modified mice will be used. Aim 2 will investigate the role of cell excitation and calcium cycling as mechanisms for PDE1i inotropy. We will test ion fluxes across the sarcolemmal membrane and SR combining patch clamping and confocal imaging using calcium indicators in guinea pig myocytes. Finally, in Aim 3 we will evaluate the arrhythomogenic effects of long-term PDE1i and expose any potential mechanisms in comparison to chronic PDE3i. Healthy or heart failure guinea pigs treated with PDE1 or PDE3 inhibitor will undergo ex vivo optical mapping mechanocoupling study or serial, conscious electrocardiogram study using telemetry device. PDE1i has completed clinical evaluation in heart failure patients. Thus, understanding how these PKA signaling pathways differ will critically guide future trial designs. Moreover, using rational design from the knowledge this study produces, we can refine the next generation of inotropes and other heart failure drugs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $541,088 )
2026	2026	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	000	3	2/23/2026	NON-COMPETING CONTINUATION	$541,088
														Subtotal = $541,088

Issue Date FY: 2025 ( Subtotal = $702,405 )
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	002	2	6/6/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	000	2	12/15/2024	NON-COMPETING CONTINUATION	$553,941
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	001	2	1/27/2025	SUPPLEMENT FOR EXPANSION	$86,915
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	003	2	8/27/2025	NON-COMPETING CONTINUATION	$61,549
														Subtotal = $702,405

Issue Date FY: 2024 ( Subtotal = $591,874 )
2024	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	001	1	6/21/2024	NEW	$57,227
2024	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Cardiovascular Diseases Research	000	1	1/22/2024	NEW	$534,647
														Subtotal = $591,874

Grand Total All Awards = $1,835,367

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Phosphodiesterase 1 (PDE1) Regulation of Myocardial Calcium and Function

Award Number: R01HL171586

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/22/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer